[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5478/MSL.2021.12.4.172

Identification of HYIpro-3-1 Metabolites, a Novel Anti-Inflammatory Compound, in Human Liver Microsomes by Quadrupole-Orbitrap High-Resolution Mass Spectrometry

Bai, Honghao (BK21 Plus KNU Multi-Omics based Creative Drug Research Team, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Kim, Younah (BK21 Plus KNU Multi-Omics based Creative Drug Research Team, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Paudel, Sanjita (BK21 Plus KNU Multi-Omics based Creative Drug Research Team, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lee, Eung-Seok (College of Pharmacy, Yeungnam University)
Lee, Sangkyu (BK21 Plus KNU Multi-Omics based Creative Drug Research Team, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)

Publication Information

Mass Spectrometry Letters / v.12, no.4, 2021 , pp. 172-178 More about this Journal

Abstract

HYIpro-3-1 is an adjuvant for preventing or treating inflammatory growth diseases. In this study, we identified the metabolic pathway of HYIpro-3-1 in human liver microsomes (HLMs) by quadrupole-orbitrap high-resolution mass spectrometry (HR-MS) and characterized the major human cytochrome P450 (CYP). Ten metabolites were identified, including one O-demethylation (M1), two O-demethylation and monohydroxylation (M2 and M3), and seven monohydroxylation metabolites (M4-M10). Based on the HR-MS² spectra, the metabolites are divided into two groups of monohydroxylated metabolites according to the hydroxylation position. We verified that HYIpro-3-1 is metabolized by CYP in HLMs, CYP2B6 is mainly involved in O-demethylation, and various CYPs are involved in the monohydroxylation of HYIpro-3-1.

Keywords

HYIpro-3-1; LC-HR/MS; cytochrome P450; human liver microsomes;

Citations & Related Records

Reference

1	Meyer, M. R.; Maurer, H. H. Anal. Bioanal. Chem. 2012, 403, 1221, DOI: 10.1007/s00216-012-5807-z. DOI
2	Zhu, M.; Zhang, H.; Humphreys, W. G. J. Biol. Chem. 2011, 286, 25419, DOI: 10.1074/jbc.R110.200055. DOI
3	Kim, Y.; Shrestha, R.; Kim, S.; Kim, J. A.; Lee, J.; Jeong, T. C.; Kim, J. H.; Lee, S. Xenobiotica 2020, 50, 380, DOI:10.1080/00498254.2019.1636418. DOI
4	Cho, P. J.; Paudel, S.; Lee, D.; Jin, Y. J.; Jo, G.; Jeong, T. C.; Lee, S.; Lee, T. Pharmaceutics 2018, 10. DOI:10.3390/pharmaceutics10030141. DOI
5	Thevis, M.; Thomas, A.; Schanzer, W. Anal. Bioanal. Chem. 2011, 401, 405, DOI: 10.1007/s00216-011-4859-9. DOI
6	Kadayat, T. M.; Banskota, S.; Gurung, P.; Bist, G.; Thapa Magar, T. B.; Shrestha, A.; Kim, J. A.; Lee, E. S. Eur. J. Med. Chem. 2017, 137, 575, DOI: 10.1016/j.ejmech.2017.06.018. DOI
7	Emoto, C.; Murase, S.; Sawada, Y.; Jones, B. C.; Iwasaki, K. Drug Metab. Pharmacokinet. 2003, 18, 287, DOI:10.2133/dmpk.18.287 DOI